Universe Pharmaceuticals INC Reports Financial Results for The First Six Months of Fiscal Year 2024
Universe Pharmaceuticals INC (Nasdaq: UPC) reported financial results for the first six months of fiscal year 2024 ended March 31, 2024. The company faced business uncertainties and a global economic slowdown, resulting in a 30.2% decrease in revenue to $12.9 million compared to $18.5 million in the same period last year. Key financial highlights include:
- Loss from operations of $1.7 million, compared to an income of $0.1 million in the previous year
- Net loss of $13.1 million, compared to a net loss of $0.7 million in the previous year
- Loss per share of $3.59, compared to $0.20 in the previous year
The company is focusing on developing online sales channels and implementing digital marketing strategies to improve brand recognition and expand its customer base. On July 15, 2024, Universe Pharmaceuticals closed a self-underwritten public offering, raising $25 million before expenses.
Universe Pharmaceuticals INC (Nasdaq: UPC) ha riportato i risultati finanziari per i primi sei mesi dell'anno fiscale 2024, conclusisi il 31 marzo 2024. L'azienda ha affrontato incertezze aziendali e un rallentamento economico globale, che ha portato a una riduzione del 30,2% dei ricavi, scendendo a 12,9 milioni di dollari rispetto ai 18,5 milioni dello stesso periodo dell'anno precedente. I principali punti finanziari includono:
- Perdita operativa di 1,7 milioni di dollari, rispetto a un utile di 0,1 milioni dell'anno precedente
- Perdita netta di 13,1 milioni di dollari, rispetto a una perdita netta di 0,7 milioni dell'anno scorso
- Perdita per azione di 3,59 dollari, rispetto a 0,20 dollari dell'anno precedente
L'azienda sta puntando a Sviluppare canali di vendita online e implementare strategie di marketing digitale per migliorare il riconoscimento del marchio e ampliare la sua base clienti. Il 15 luglio 2024, Universe Pharmaceuticals ha chiuso un offerta pubblica autogestita, raccogliendo 25 milioni di dollari prima delle spese.
Universe Pharmaceuticals INC (Nasdaq: UPC) informó sobre los resultados financieros de los primeros seis meses del año fiscal 2024, finalizado el 31 de marzo de 2024. La empresa enfrentó incertidumbres comerciales y un desaceleramiento económico global, resultando en una disminución del 30,2% en los ingresos, que alcanzaron los 12,9 millones de dólares en comparación con los 18,5 millones del mismo período del año pasado. Los aspectos financieros clave incluyen:
- Pérdida de operaciones de 1,7 millones de dólares, en comparación con una ganancia de 0,1 millones del año anterior
- Pérdida neta de 13,1 millones de dólares, en comparación con una pérdida neta de 0,7 millones del año anterior
- Pérdida por acción de 3,59 dólares, en comparación con 0,20 dólares del año anterior
La empresa se está enfocando en desarrollar canales de venta en línea e implementar estrategias de marketing digital para mejorar el reconocimiento de la marca y expandir su base de clientes. El 15 de julio de 2024, Universe Pharmaceuticals cerró una oferta pública autogestionada, levantando 25 millones de dólares antes de gastos.
유니버스 제약 주식회사 (Nasdaq: UPC)는 2024 회계연도 첫 6개월의 재무 결과를 2024년 3월 31일 기준으로 보고했습니다. 회사는 사업 불확실성과 글로벌 경제 둔화에 직면하여, 매출이 30.2% 감소하여 1,290만 달러에 그친 반면, 작년 같은 기간에는 1,850만 달러였습니다. 주요 재무 하이라이트는 다음과 같습니다:
- 영업 손실이 170만 달러, 작년에는 10만 달러의 수익이 있었음
- 순손실이 1,310만 달러, 작년에는 순손실 70만 달러였음
- 주당 손실이 3.59달러, 작년에는 0.20달러였습니다
회사는 온라인 판매 채널 개발과 디지털 마케팅 전략 구현에 집중하여 브랜드 인지도를 향상시키고 고객 기반을 확장하고 있습니다. 2024년 7월 15일, 유니버스 제약은 자기 주관적 공적 제공을 마감하며, 경비 제외 2,500만 달러를 모금했습니다.
Universe Pharmaceuticals INC (Nasdaq: UPC) a rapporté les résultats financiers des six premiers mois de l'exercice 2024, qui s'est terminé le 31 mars 2024. L'entreprise a fait face à des incertitudes commerciales et un ralentissement économique mondial, entraînant une diminution de 30,2 % des revenus, qui sont tombés à 12,9 millions de dollars contre 18,5 millions de dollars pour la même période l'année précédente. Les points financiers clés incluent :
- Perte d'exploitation de 1,7 million de dollars, par rapport à un bénéfice de 0,1 million l'année précédente
- Perte nette de 13,1 millions de dollars, contre une perte nette de 0,7 million l'année précédente
- Perte par action de 3,59 dollars, par rapport à 0,20 dollars l'année dernière
L'entreprise se concentre sur le développement de canaux de vente en ligne et l'implémentation de stratégies de marketing numérique pour améliorer la reconnaissance de la marque et élargir sa base de clients. Le 15 juillet 2024, Universe Pharmaceuticals a clôturé une offre publique autofinancée, levant 25 millions de dollars avant dépenses.
Universe Pharmaceuticals INC (Nasdaq: UPC) hat die finanziellen Ergebnisse für die ersten sechs Monate des Geschäftsjahres 2024, die am 31. März 2024 endeten, bekannt gegeben. Das Unternehmen sah sich geschäftlichen Unsicherheiten und einem globalen Wirtschaftsrückgang gegenüber, was zu einem Rückgang der Einnahmen um 30,2% auf 12,9 Millionen Dollar im Vergleich zu 18,5 Millionen Dollar im gleichen Zeitraum des Vorjahres führte. Wichtige finanzielle Höhepunkte sind:
- Betriebsverlust von 1,7 Millionen Dollar, im Vergleich zu einem Gewinn von 0,1 Millionen im Vorjahr
- Nettoverlust von 13,1 Millionen Dollar, im Vergleich zu einem Nettoverlust von 0,7 Millionen im Vorjahr
- Verlust pro Aktie von 3,59 Dollar, im Vergleich zu 0,20 Dollar im Vorjahr
Das Unternehmen konzentriert sich auf die Entwicklung von Online-Vertriebskanälen und die Implementierung von digitalen Marketingstrategien, um die Markenbekanntheit zu steigern und die Kundenbasis zu erweitern. Am 15. Juli 2024 schloss Universe Pharmaceuticals eine eigenverantwortliche öffentliche Angebot, die 25 Millionen Dollar vor Ausgaben einbrachte.
- Initiated development of online sales channels to complement offline sales
- Implemented digital marketing strategies to improve brand recognition
- Raised $25 million through a public offering of 20,000,000 ordinary shares
- Revenue decreased by 30.2% to $12.9 million
- Loss from operations of $1.7 million compared to income of $0.1 million in previous year
- Net loss increased to $13.1 million from $0.7 million in previous year
- Loss per share increased to $3.59 from $0.20 in previous year
- Gross margin decreased by 7.0% to 26.2%
- Realized loss on short-term investments of $3,094,084
- Change in fair value of short-term investment resulted in a loss of $7,617,502
Insights
Universe Pharmaceuticals' latest financial results reveal significant challenges. Revenue declined by
Key concerns include:
- Decreased sales volumes in both TCMD (
23.4% ) and third-party products (29.9% ) - Gross margin compression from
33.2% to26.2% - Significant increase in advertising expenses (
$1.4 million )
Universe Pharmaceuticals' performance reflects broader market challenges in China's pharmaceutical sector. The global economic slowdown has significantly impacted consumer spending power, leading to decreased demand for both TCMD and third-party products. The company's pivot towards online sales channels and increased digital marketing efforts is a strategic move, but results are yet to materialize.
Key market factors influencing performance:
- Economic uncertainty affecting consumer healthcare spending
- Supply chain disruptions (e.g., floods in Anhui and Hubei provinces) increasing raw material costs
- Shift in consumer behavior towards e-commerce platforms
Universe Pharmaceuticals' financial results raise significant red flags for investors. The company's risk profile has deteriorated substantially, with several concerning trends:
- Operational losses indicating core business challenges
- Substantial losses from short-term investments, suggesting poor risk management
- Negative cash flow from operations (
$2.4 million ) - Increased reliance on financing activities for cash
JI’AN, Jiangxi, China, Sept. 20, 2024 (GLOBE NEWSWIRE) -- Universe Pharmaceuticals INC (the “Company,” “we,” “our” and “us”) (Nasdaq: UPC), a pharmaceutical producer and distributor in China, today announced its unaudited financial results for the first six months of fiscal year 2024 ended March 31, 2024.
Mr. Gang Lai, Chairman of the Board of Directors and CEO of Universe Pharmaceuticals INC, commented, “During the first six months of fiscal year 2024, we navigated business uncertainties and adjusted our business strategy to offset the impact of the global economic slowdown. As a result, we generated
Financial Highlights for the Six Months Ended March 31, 2024
For the Six Months Ended March 31, | ||||||||||||
($ millions, except per share data) | 2024 | 2023 | % Change | |||||||||
Revenues | 12.9 | 18.5 | -30.2 | % | ||||||||
(Loss) income from operations | (1.7 | ) | 0.1 | -1,266.0 | % | |||||||
Net loss | (13.1 | ) | (0.7 | ) | 1,731.3 | % | ||||||
Loss per share | (3.59 | ) | (0.20 | ) | 1,720.7 | % |
- Revenues decreased by
30.2% to$12.9 million for the six months ended March 31, 2024 from$18.5 million for the six months ended March 31, 2023, primarily attributable to decreased sales volume of the Company’s traditional Chinese medicine derivatives (“TCMD”) products and third-party products by 1,863,919 and 1,712,660 units, or23.4% and29.9% , respectively, due to decrease in customer demand resulted from economic slowdown, as well as a3.3% negative impact from fluctuations in foreign currency exchange rate. - Loss from operations was
$1.7 million for the six months ended March 31, 2024, compared to an income from operations of$0.1 million for the six months ended March 31, 2023, due to the decrease in revenue as discussed above. - Net loss was
$13.1 million for the six months ended March 31, 2024, compared to a net loss of$0.7 million for the six months ended March 31, 2023. Realized loss on short-term investments from wealth management financial products was$3,094,084 for the six months ended March 31, 2024, compared to short-term investment income of$166,931 for the six months ended March 31, 2023. The Company also recorded change in fair value of short-term investment of$7,617,502 for its investment holdings during the six months ended March 31, 2024. No change in fair value of short-term investment was recognized for the six months ended March 31, 2023. - Loss per share was
$3.59 for the six months ended March 31, 2024, compared to loss per share of$0.20 for the six months ended March 31, 2023.
Financial Results for the Six Months Ended March 31, 2024 Compared to the Six Months Ended March 31, 2023
Revenues
Total revenues decreased by
For the Six Months Ended March 31, | ||||||||||||||||||||||
2024 | 2023 | |||||||||||||||||||||
Revenue | Cost of revenue | Gross margin | Revenue | Cost of revenue | Gross margin | |||||||||||||||||
TCMD products sales | $ | 6,870,591 | $ | 5,602,807 | 18.5 | % | $ | 9,374,312 | $ | 6,617,445 | 29.4 | % | ||||||||||
Third-party products sales | 6,013,779 | 3,912,232 | 34.9 | % | 9,092,874 | 5,721,600 | 37.1 | % | ||||||||||||||
Total | $ | 12,884,370 | $ | 9,515,039 | 26.2 | % | $ | 18,467,186 | $ | 12,339,044 | 33.2 | % | ||||||||||
Sales of TCMD products decreased by
Sales of third-party products decreased by
Cost of revenues and Gross profit
Cost of revenues decreased by
Gross profit decreased by
Operating expenses
Selling expenses increased by
General and administrative expenses decreased by
Research and development expenses decreased by
Other income (expenses), net
Total other expenses, net was
Provision for income taxes
Provision for income taxes was
Net loss
Net loss was
Basic and diluted loss per share were
Balance Sheet
As of March 31, 2024, the Company had cash of
Cash Flow
Net cash used in operating activities was
Net cash used in investing activities was
Net cash provided by financing activities was
Subsequent Event
On July 15, 2024, the Company closed its self-underwritten public offering (“Offering”) of 20,000,000 ordinary shares, par value
About Universe Pharmaceuticals INC
Universe Pharmaceuticals INC, headquartered in Ji’an, Jiangxi, China, is a pharmaceutical producer and distributor in China. The Company specializes in the manufacturing, marketing, sales and distribution of traditional Chinese medicine derivatives products targeting the elderly with the goal of addressing their physical conditions in the aging process and to promote their general well-being. The Company also distributes and sells biomedical drugs, medical instruments, Traditional Chinese Medicine Pieces, and dietary supplements manufactured by third-party pharmaceutical companies. Currently, the Company’s products are sold in 30 provinces of China. For more information, visit the company’s website at http://www.universe-pharmacy.com/.
Forward-Looking Statements
All statements other than statements of historical fact in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on current expectations and projections about future events and financial trends that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. Investors can identify these forward-looking statements by words or phrases such as “may,” “will,” “expect,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “potential,” “continue,” “is/are likely to” or other similar expressions. The Company undertakes no obligation to update forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company’s most recent annual report on Form 20-F and in its other filings with the U.S. Securities and Exchange Commission.
For more information, please contact:
Email:IR@universe-pharmacy.com
Phone:+86-0796-8403687
UNIVERSE PHARMACEUTICALS INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS | ||||||||
As of | ||||||||
March 31, 2024 | September 30, 2023 | |||||||
(Unaudited) | ||||||||
ASSETS | ||||||||
CURRENT ASSETS | ||||||||
Cash | $ | 8,861,590 | $ | 5,285,247 | ||||
Short-term investments | 2,527,603 | 13,219,005 | ||||||
Accounts receivable, net | 14,384,228 | 10,667,603 | ||||||
Due from related parties | - | 61,678 | ||||||
Inventories, net | 3,386,052 | 3,343,266 | ||||||
Advance to suppliers | 368,960 | 180,643 | ||||||
Prepayment for acquisition | 3,462,460 | 3,426,535 | ||||||
Prepaid expenses and other current assets | 539,240 | 590,377 | ||||||
TOTAL CURRENT ASSETS | 33,530,133 | 36,774,354 | ||||||
Property, plant and equipment, net | 3,522,997 | 3,699,965 | ||||||
Prepayments made to a related party for purchase of property | 2,215,974 | 2,192,982 | ||||||
Prepayments for construction in progress | 9,225,725 | 9,092,996 | ||||||
Intangible assets, net | 147,652 | 148,584 | ||||||
Investment in equity securities | 692,492 | 685,307 | ||||||
Deferred tax assets | - | 656,980 | ||||||
Prepaid expenses-related party, non-current | 96,141 | 35,864 | ||||||
TOTAL NONCURRENT ASSETS | 15,900,981 | 16,512,678 | ||||||
TOTAL ASSETS | $ | 49,431,114 | $ | 53,287,032 | ||||
LIABILITIES AND SHAREHOLDERS’ EQUITY | ||||||||
CURRENT LIABILITIES | ||||||||
Short-term bank loans | $ | 4,431,949 | $ | 5,482,456 | ||||
Accounts payable | 7,763,981 | 4,585,285 | ||||||
Taxes payable | 172,374 | 434,758 | ||||||
Due to related parties | 5,515,160 | 540,096 | ||||||
Accrued expenses and other current liabilities | 2,726,078 | 2,711,736 | ||||||
TOTAL CURRENT LIABILITIES | 20,609,542 | 13,754,331 | ||||||
Long-term bank loans | 2,077,476 | - | ||||||
TOTAL LIABILITIES | 22,687,018 | 13,754,331 | ||||||
COMMITMENTS AND CONTINGENCIES | ||||||||
SHAREHOLDERS’ EQUITY | ||||||||
Ordinary shares, | 68,362 | 67,969 | ||||||
Additional paid in capital | 29,278,766 | 29,279,159 | ||||||
Statutory reserve | 2,439,535 | 2,439,535 | ||||||
Retained earnings | (2,942,153 | ) | 10,159,304 | |||||
Accumulated other comprehensive loss | (2,100,414 | ) | (2,413,266 | ) | ||||
TOTAL SHAREHOLDERS’ EQUITY | 26,744,096 | 39,532,701 | ||||||
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY | $ | 49,431,114 | $ | 53,287,032 |
UNIVERSE PHARMACEUTICALS INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME (UNAUDITED) | ||||||||
For the Six Months Ended March 31, | ||||||||
2024 | 2023 | |||||||
REVENUE | $ | 12,884,370 | $ | 18,467,186 | ||||
COST OF REVENUE AND RELATED TAX | 9,515,039 | 12,339,044 | ||||||
GROSS PROFIT | 3,369,331 | 6,128,142 | ||||||
OPERATING EXPENSES | ||||||||
Selling expenses | 4,054,357 | 2,330,508 | ||||||
General and administrative expenses | 968,608 | 1,380,053 | ||||||
Research and development expenses | 86,503 | 2,268,335 | ||||||
Total operating expenses | 5,109,468 | 5,978,896 | ||||||
INCOME (LOSS) FROM OPERATIONS | (1,740,137 | ) | 149,246 | |||||
OTHER INCOME (EXPENSES) | ||||||||
Interest expense, net | (136,613 | ) | (74,569 | ) | ||||
Other income, net | 152,027 | 17,323 | ||||||
Realized (loss) gain on short-term investments | (3,094,084 | ) | 166,931 | |||||
Change in fair value of short-term investments | (7,617,502 | ) | - | |||||
Total other (loss) income, net | (10,696,172 | ) | 109,685 | |||||
(LOSS) INCOME BEFORE INCOME TAX PROVISION | (12,436,309 | ) | 258,931 | |||||
PROVISION FOR INCOME TAXES | 665,148 | 974,358 | ||||||
NET LOSS | (13,101,457 | ) | (715,427 | ) | ||||
OTHER COMPREHENSIVE INCOME | ||||||||
Foreign currency translation adjustment | 312,852 | 1,399,775 | ||||||
COMPREHENSIVE (LOSS) INCOME | $ | (12,788,605 | ) | $ | 684,348 | |||
Earnings per ordinary share - basic and diluted | $ | (3.59 | ) | $ | (0.20 | ) | ||
Weighted average shares - basic and diluted * | $ | 3,645,974 | $ | 3,625,000 |
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS’ EQUITY FOR THE SIX MONTHS ENDED MARCH 31, 2024 AND 2023 (UNAUDITED) | ||||||||||||||||||||||||||||
Accumulated | ||||||||||||||||||||||||||||
Additional | Other | |||||||||||||||||||||||||||
Ordinary Share | Paid in | Statutory | Retained | Comprehensive | ||||||||||||||||||||||||
Shares | Amount | Capital | Reserve | Earnings | Income | Total | ||||||||||||||||||||||
Balance at September 30, 2022 | 3,625,000 | $ | 67,969 | $ | 29,279,159 | $ | 2,439,535 | $ | 16,322,365 | $ | (1,666,705 | ) | $ | 46,442,323 | ||||||||||||||
Net loss | - | - | - | - | (715,427 | ) | - | (715,427 | ) | |||||||||||||||||||
Foreign currency translation adjustment | - | - | - | - | - | 1,399,775 | 1,399,775 | |||||||||||||||||||||
Balance at March 31, 2023 | 3,625,000 | $ | 67,969 | $ | 29,279,159 | $ | 2,439,535 | $ | 15,606,938 | $ | (266,930 | ) | $ | 47,126,671 | ||||||||||||||
Accumulated | ||||||||||||||||||||||||||||
Additional | Other | |||||||||||||||||||||||||||
Ordinary Share | Paid in | Statutory | Retained | Comprehensive | ||||||||||||||||||||||||
Shares | Amount | Capital | Reserve | Earnings | Income | Total | ||||||||||||||||||||||
Balance at September 30, 2023 | 3,625,000 | $ | 67,969 | $ | 29,279,159 | $ | 2,439,535 | $ | 10,159,304 | $ | (2,413,266 | ) | $ | 39,532,701 | ||||||||||||||
Reverse share-split adjustment | 20,974 | 393 | (393 | ) | - | - | - | - | ||||||||||||||||||||
Net loss | - | - | - | - | (13,101,457 | ) | - | (13,101,457 | ) | |||||||||||||||||||
Foreign currency translation adjustment | - | - | - | - | - | 312,852 | 312,852 | |||||||||||||||||||||
Balance at March 31, 2024 | 3,645,974 | $ | 68,362 | $ | 29,278,766 | $ | 2,439,535 | $ | (2,942,153 | ) | $ | (2,100,414 | ) | $ | 26,744,096 |
UNIVERSE PHARMACEUTICALS INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) | ||||||||
For the Six Months Ended March 31, | ||||||||
2024 | 2023 | |||||||
Cash flows from operating activities: | ||||||||
Net loss | $ | (13,101,457 | ) | $ | (715,427 | ) | ||
Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||
Depreciation and amortization | 248,860 | 257,781 | ||||||
Gain from disposal of fixed assets | - | (115 | ) | |||||
Changes in allowance for doubtful accounts | (265,530 | ) | - | |||||
Changes in inventory reserve | (34,303 | ) | (84,956 | ) | ||||
Deferred income tax provision | 665,148 | 556,867 | ||||||
Realized loss (gain) on short-term investments | 3,094,084 | (166,931 | ) | |||||
Change in fair value of short-term investments | 7,617,502 | - | ||||||
Changes in operating assets and liabilities: | ||||||||
Accounts receivable | (3,346,205 | ) | (1,763,903 | ) | ||||
Inventories | 26,553 | (488,746 | ) | |||||
Advance to suppliers, net | (186,782 | ) | (187,460 | ) | ||||
Prepaid expenses and other current assets | 57,436 | (220,969 | ) | |||||
Prepaid expenses-related party, non-current | (60,016 | ) | - | |||||
Accounts payable | 3,136,661 | 7,928,308 | ||||||
Taxes payable | (267,456 | ) | 149,684 | |||||
Accrued expenses and other current liabilities | (14,116 | ) | (465,431 | ) | ||||
Net cash (used in) provided by operating activities | (2,429,621 | ) | 4,798,702 | |||||
Cash flows from investing activities: | ||||||||
Purchases of property and equipment | (30,189 | ) | (646 | ) | ||||
Prepayments for construction in progress | (37,467 | ) | - | |||||
Purchase of short-term investments | (313,541 | ) | ||||||
Sale of short-term investments | 313,541 | |||||||
Net cash used in investing activities | (67,656 | ) | (646 | ) | ||||
Cash flows from financing activities: | ||||||||
Proceeds from bank loans | 2,081,483 | 1,146,776 | ||||||
Repayment of bank loans | (1,110,124 | ) | (1,146,776 | ) | ||||
Proceeds from related party borrowings | 5,096,373 | 2,080,918 | ||||||
Net cash provided by financing activities | 6,067,732 | 2,080,918 | ||||||
Effect of changes of foreign exchange rates on cash | 5,888 | 364,084 | ||||||
Net increase in cash | 3,576,343 | 7,243,058 | ||||||
Cash, beginning of period | 5,285,247 | 5,711,458 | ||||||
Cash, end of period | $ | 8,861,590 | $ | 12,954,516 | ||||
Supplemental disclosure of cash flow information | ||||||||
Cash paid for interest | $ | 148,861 | $ | 90,044 | ||||
Cash paid for income tax | $ | 969,914 | $ | 575,132 |
FAQ
What was Universe Pharmaceuticals' (UPC) revenue for the first six months of fiscal year 2024?
How much did Universe Pharmaceuticals' (UPC) net loss increase in the first half of fiscal year 2024?
What was the loss per share for Universe Pharmaceuticals (UPC) in the first half of fiscal year 2024?